DBVT DBV Technologies S.A.
DBV Technologies S.A. (DBVT) is expected to report earnings on October 15, 2026, after the market close. The consensus earnings estimate is a loss of $0.60 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.4% since its last earnings release on July 16, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About DBV Technologies S.A.
DBV Technologies SA is an epicutaneous immunotherapy company. The Company is engaged in research and development of patient-friendly therapy for food and pediatric allergy patients.
Sector
Healthcare
Industry
Biotechnology